日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy.

通过抑制自噬,同时靶向 FLT3 和 BTK 可以克服急性髓系白血病中 FLT3 抑制剂的耐药性

Zhang Weiguo, Yu Guopan, Zhang Hongying, Basyal Mahesh, Ly Charlie, Yuan Bin, Ruvolo Vivian, Piya Sujan, Bhattacharya Seemana, Zhang Qi, Borthakur Gautam, Battula Venkata, Konopleva Marina, Rice William G, Andreeff Michael

The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and Aurora kinases

多激酶抑制剂CG-806通过共同靶向FLT3、BTK和Aurora激酶,发挥抗急性髓系白血病的活性。

Yu, Guopan; Zhang, Weiguo; Zhang, Hongying; Ly, Charlie; Basyal, Mahesh; Rice, William G; Andreeff, Michael

APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency

APTO-253 是可利用 DNA BRCA1/2 缺陷的药物库中的新成员

Tsai, Cheng-Yu; Sun, Si; Zhang, Hongying; Local, Andrea; Su, Yongxuan; Gross, Larry A; Rice, William G; Howell, Stephen B

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

抑制 RNA 聚合酶 I 作为促进 p53 癌症特异性激活的治疗策略

Bywater Megan J, Poortinga Gretchen, Sanij Elaine, Hein Nadine, Peck Abigail, Cullinane Carleen, Wall Meaghan, Cluse Leonie, Drygin Denis, Anderes Kenna, Huser Nanni, Proffitt Chris, Bliesath Joshua, Haddach Mustapha, Schwaebe Michael K, Ryckman David M, Rice William G, Schmitt Clemens, Lowe Scott W, Johnstone Ricky W, Pearson Richard B, McArthur Grant A, Hannan Ross D